total score for each SB-773812 dose versus placebo at Week 6.
Evaluate safety of SB-773812 versus placebo and compared to olanzapine using PANNS scores -Measure the preliminary pharmacokinetic/pharmacodynamic relationships for SB-773812 -Assessment of movement disorders and cognitive functioning
18 Years to 65 Years (Adult)
December 1, 2005
March 23, 2017
GSK Investigational Site Birmingham, Alabama, United States
GSK Investigational Site Cerritos, California, United States
GSK Investigational Site Garden Grove, California, United States
(and 42 more...)
† Study has passed its completion date and status has not been verified in more than two years.